Canada Cannabis for GI Disease Market Report

Canada Cannabis for
GI Disease Market
Canada Cannabis for GI Disease Market – Segmented
by- by Application, Forecast 2020 till 2028
Sample Report

2 Confidential
Sample
1. Canada Cannabis for GI Disease Market Overview……………………………………..…………………………..………………………………………………..05
a. Methodology and Scope
b. Market Overview
2. Market Growth Drivers………………………………………………………………………………………………………...............................................................14
a. Increase in Prevalence for Rise in Intake of Cannabis for GI Disease Market
b. Increase Awareness among Consumers Regarding Health Benefits of Cannabis
c. High Investment into Research and Development
3. Market Restraints………………………………………………………………………………………………..................................................................................17
a. Legal and Reimbursement Issues
b. Side effects of Cannabis
4. Cannabis for GI Disease Market Segmentation……………………………………………………………………………………………………………………….…18
a. By Application
i. Recreational
ii. Medical
b. By Product Type
i. Flowers
ii. Concentrates
iii.Others
Table of Content

3 Confidential
Table of Content
Sample
5. Competitive Landscape……………………………...………………………………………………………………………….........................................................22
a. Key Players Revenue
b. Start-ups Leveraging Cannabis for GI Disease Market
6. Key Company Profiles…………………………….……………………………………………………………………………………………………………..…….....25
a. Canopy Growth Corporation overview, Product & Services, Strategies & Financials
b. CanniMed Limited , Product & Services, Strategies & Financials
c. Cannabis Sativa Inc., Product & Services, Strategies & Financials
d. Emerald Health Therapeutics Inc., Product & Services, Strategies & Financials
e. GB Sciences Inc., Product & Services, Strategies & Financials
f. Cara Therapeutics, Product & Services, Strategies & Financials
g. Pfizer Company, Product & Services, Strategies & Financials
h. MediPharm Labs Company, Product & Services, Strategies & Financials
7. R&D Initiatives by Major Companies…………………………………………………………………………………………………………………………………..42
a. R&D Expenditure by Major Companies
b. R&D Expenditure in Canada Cannabis Market
8. Access and Reimbursement Scenario…………………………………………………….…………………………………………………………………………..45
a. Key Market Access Considerations
b. General Reimbursement Environment

4 Confidential
Table of Content
Sample
9. Future Development Growth ………………………………………………………………………….……………………….........................................................47
a. Key Players Revenue
b. Various Start-ups Leveraging Cannabis for GI Disease Market
10. Conclusion…………………………….…………………………………………..………………………………………………………………………………..……....50

6 Confidential
Methodology and Scope
Research Methodology
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conducted extensive data mining, referring to verified data sources such as independent studies,
government and regulatory published material, technical journals, trade magazines, and paid data sources. This forms the basis of our
estimates
▪ For forecasting, the following parameters were considered:
o Market drivers and restraints along with their current and expected impacts
o Technological scenario and expected developments
o End use industry trends and dynamics
o Trends in the consumer behavior
▪ We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the
expected market growth rate
▪ All our estimates and forecasts were verified through exhaustive primary research with the Key Industry Participants (KIPs)

7 Confidential
Methodology and Scope (continued)
Research Scope and Assumption
▪ The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD Billion). The
market for each type has been provided on a regional basis for the above-mentioned forecast period
▪ The key industry dynamics, regulatory scenario, major technological trends, and application markets are evaluated to understand their
impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
▪ We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and
trends for various solutions, services, and end uses. The global market has been estimated by integrating the regional markets
▪ All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs)
▪ Inflation has not been accounted for in order to estimate and forecast the market
▪ Numbers may not add up due to rounding off

8 Confidential
List of Data Sources used in this Report
▪ Some of the secondary sources used for this report include but are not limited to:
o Canada government annual reports
o Federal Health Reforms Related to Cannabis for GI disease
o Funding Reports
o Annual Reports 2020 – For Key Market Players
o Government resources supporting Cannabis for GI disease
▪ Some of the primary sources used for this report include but are not limited to:
o Surveys through Questionnaires
o Interviews with Key Opinion Leaders
o Field surveys

9 Confidential
Key Benefit for Stakeholders from this Report
▪ The study provides an in-depth analysis of the Canada cannabis for GI disease treatment market with current trends and future
estimations to elucidate the imminent investment pockets
▪ Comprehensive analysis of factors that drive and restrict the market growth is provided.
▪ Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the
prevailing market opportunities
▪ Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
▪ Key market players and their strategies are provided to understand the competitive outlook of the market

Canada Cannabis for GI Disease: Market
Overview

11 Confidential
Canada Cannabis for GI Disease Market Overview (Current and
Forecasted)
Canada Cannabis for GI Disease ($ CA Bn) (2020-2028)
▪ The Canada cannabis for GI Disease market accounted for $CA
2.6 Bn in 2020 and is expected to grow during the forecast period
▪ Medical cannabinoid products are widely used in Canada to treat
medical symptoms of all kinds, and gastrointestinal (GI) symptoms
are among the most cited reasons for use
▪ Cannabis is also widely used recreationally, and legalization of
recreational use has occurred in Canada. Cannabis can be
beneficial for individuals taking opioid medications for abdominal
pain
▪ Research shows that cannabis helps patients cut down on or
eliminate their need for opioids and provides treatment with fewer
side effects. With legalization of cannabis in Canada as of 2018,
we hope to see more research, dialogue, and deeper
understanding of how cannabis works in humans
2020 2021 2022 2023 2024 2025 2026 2027 2028
2.6
xx
Key Analysis

Canada Cannabis for GI Disease Market: Growth
Drivers and Growth Restraints

13 Confidential
Market Growth Drivers and Restraints
Increased Prevalence for
rise in Intake of Cannabis
for GI disease
High Investment into
Research and
Development
Increased Awareness
among Consumers
regarding Health benefits
of Cannabis
Side effects of Cannabis
Legal & Reimbursement
Issues
Impact
Impact
Market
Drivers
Market
Restraints

14 Confidential
Market Growth Drivers
1. Increased Prevalence for Rise in Intake of Cannabis for GI disease
Legalization of cannabis has allowed people to practice safe substance usage along with realizing its medicinal benefits,
which has led to a substantial increase in use of cannabis for GI Disease in Canada
Current research indicates that some conditions may be clinically improved by cannabis use. These include inflammatory
bowel disease, multiple sclerosis, neuropathic pain, nausea and vomiting caused by cancer or chemotherapy, pediatric
seizure disorders, and a wide variety of other illnesses
It seems to universally be effective at reducing abdominal pain. It can be especially useful for individuals taking opioid
medications for abdominal pain, as research shows that cannabis helps patients cut down on or eliminate their need for
opioids and provides a treatment with fewer side effects

15 Confidential
Market Growth Drivers (continued)
2. Increased Awareness among Consumers Regarding Health benefits of Cannabis
According to 2020 Canadian Cannabis Survey, more than half of those who use cannabis choose to obtain it through a
legal source. 41% reported legal storefront as their usual source, an increase from 24% in 2019, whereas 13% reported
obtaining cannabis from a legal online source
Almost 8 in 10 Canadians feel they have access to trustworthy information to make informed decisions about their
cannabis use. An increase from 71% in 2019 to 77% in 2020. Information about the health risks associated with cannabis
use is widely available and reaching Canadians
The marijuana plant Cannabis sativa and its derivatives, cannabinoids, have grown increasingly popular as a potential
therapy for inflammatory bowel disease (IBD), and the awareness regarding the same has increased in Canada

16 Confidential
Market Growth Drivers (continued)
3. High Investment into Research and Development
The Canadian Centre on Substance Use and Addiction (CCSA) is investing $1.8 million dollars in research on non-
therapeutic cannabis and the impacts of its legalization on public health and safety throughout the country
Through financial support from Health Canada, CCSA is funding 19 projects on subjects ranging from cannabis
legalization and mental health to a comparison of legal versus illicit cannabis sales
Content
Sample

17 Confidential
Market Restraints
▪ Breathing problems: Marijuana smoke irritates the lungs,
and people who smoke marijuana frequently can have the
same breathing problems as those who smoke tobacco.
These problems include daily cough and phlegm, more
frequent lung illness, and a higher risk of lung infections
▪ Increased heart rate: Marijuana raises heart rate for up to 3
hours after smoking. This effect may increase the chance of
heart attack
▪ Content
▪ Content
▪ The Task Force recommends that the federal government set
a national minimum age of purchase of 18, acknowledging the
right of provinces and territories to harmonize it with their
minimum age of purchase of alcohol
▪ There are various regulations owing to the misuse of cannabis
in Canadian Market
▪ Content
▪ Content
Sample Sample
Legal & Reimbursement Issues Side Effects of Cannabis

Canada Cannabis for GI Disease Market
Segmentation

19 Confidential
Market Segmentation
Cannabis for GI Disease Market
By Application By Product Type
▪ Recreational
▪ Medical
▪ Flowers
▪ Concentrates
▪ Others
Sample

20 Confidential
Market Segmentation: By Application
▪ By application, the market is segmented into medical and
recreational
▪ Recreational segment dominated the market owing to the high
demand and consumption of cannabis for recreational
purposes
▪ Thus, the legalization of recreational applications has huge
potential to translate into a large market
▪ Content
▪ Content
Recreational Medical
Sample
Market Share, by Application Key Analysis

21 Confidential
Market Segmentation: By Product Type
▪ Based on product type, concentrates is the fastest-growing
segment in the market, but flowers have the highest growth
▪ The growth of this segment is majorly attributed to its ease in
usage and its versatility in the method of delivery
▪ These concentrates are offered in the form of dabbing,
ingestible oils, and tinctures. They also offer cleaner and
smoother hits than the flower
▪ Content
▪ Content
Flowers Concentrates Others
Sample
Market Share, by Product Type Key Analysis

23 Confidential
Competitive Landscape: Key Players Revenue (Current and Forecasted)
2020 2021 2022 2023 2024 2025 2026 2027 2028
Canopy Growth
Corporation
300 - - - - - - - -
CanniMed Ltd. 51.1 - - - - - - - -
Cannabis Sativa Inc. 2.1 - - - - - - - -
Emerald Health
Therapeutics Inc.
2.9 - - - - - - - -
GB Sciences Inc. 3.1 - - - - - - - -
Cara Therapeutics 0.1 - - - - - - - -
Pfizer 419 - - - - - - - -
MediPharm 36 - - - - - - - -
Major Market Revenue of Key Players ($Mn)

24 Confidential
Start ups Leveraging Cannabis for GI Disease Market
Ample Organics is an information technology company that offers enterprise seed-to-sale inventory
software for the cannabis industry. The company was founded in 2014 and based in Toronto,
Ontario
Canopy Health Innovations, a bio-pharmaceutical company focused on developing innovative
cannabis-based related products. The goal is to develop a range of effective formulations and
delivery mechanisms that serve patients worldwide
Lobo Genetics is a healthcare technology start up company with the goal of helping you better
understand your response to cannabis through genetics
Aurora Cannabis, Inc. engages in the production, distribution and sale of cannabis products. It also
produces and sells indoor cultivation systems and hemp related food products
HEXO Corp is a consumer packaged goods cannabis company that creates and distributes prize-
winning products to serve the global
Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult
recreational consumers in Canada, as well as developing international business partnerships
to extend the Company’s global footprint

26 Confidential
Canopy Growth Corporation
▪ Canopy Growth is a diversified cannabis and cannabinoid-
based consumer product company, driven by a passion to
improve lives, end prohibition, and strengthen communities by
unleashing the full potential of cannabis
▪ Leveraging consumer insights and innovation, it offer product
varieties in high-quality dried flower, oil, soft gel capsule,
infused beverage, edible, and topical formats, as well as
vaporizer devices by Canopy Growth and industry-leader
Storz & Bickel
▪ Canopy Growth has acquired 17 organizations. Their most
recent acquisition was Supreme Cannabis on Apr 8,
2021. They acquired Supreme Cannabis for $435M
Company Name: Canopy Growth
Corporation
Year of Establishment: 2014
Headquarter: Ontario, Canada
Revenue: $300 million
Website: https://www.canopygrowth.com/
Company Profile

27 Confidential
Canopy Growth Corporation
2020 2024 2028
Analysis
▪ The company is profiled for the financial year ended, 2028
▪ Content
Sample
Revenues ($ Mn), 2020-2028 Breakdown of Net Sales (%) by segment, 2020

28 Confidential
Cannabis Sativa Inc.
▪ Cannabis Sativa, Inc. develops and promotes natural cannabis
products. The Company is engaged in the research,
development and licensing of natural cannabis products,
including cannabis formulas, edibles, topicals, strains, recipes
and delivery systems
▪ The Company plans to develop, produce and market products
through joint ventures with companies licensed under state
regulations applicable to cannabis businesses
▪ It holds the license for a medicinal cannabis strain called NZT,
a cannabis lozenge delivery methodology, and a cannabis
trauma cream formula. The Company is also developing a
third strain of cannabis plant named CT22
Company Name: Cannabis Sativa Inc.
Year of Establishment: 2005
Headquarter: United States
Revenue: $2.04 million
Website: http://cannabissativainc.com/
Company Profile

29 Confidential
Cannabis Sativa Inc.
2020 2024 2028
Analysis
▪ Content
Sample

30 Confidential
CanniMed Limited
Company Name:
Year of Establishment:
Headquarter:
Revenue:
Website:
Company Profile
Sample
Sample

31 Confidential
CanniMed Limited
2020 2024 2028
Analysis
▪ Content
Sample

32 Confidential
Emerald Health Therapeutics Inc.
Company Name:
Headquarter:
Revenue:
Website:
Sample
Company Profile
Sample

33 Confidential
Emerald Health Therapeutics Inc.
2020 2024 2028
Analysis
▪ Content
Sample

34 Confidential
G B Sciences Inc.
Company Name:
Headquarter:
Revenue:
Website:
Company Profile
Sample
Sample

35 Confidential
G B Sciences Inc.
2020 2024 2028
Analysis
▪ Content
Sample

36 Confidential
Cara Therapeutics
Company Name:
Headquarter:
Revenue:
Website:
Company Profile
Sample
Sample

37 Confidential
Cara Therapeutics
2020 2024 2028
Analysis
▪ Content
Sample

38 Confidential
Pfizer
Company Name:
Headquarter:
Revenue:
Website:
Company Profile
Sample
Sample

39 Confidential
Pfizer
2020 2024 2028
Analysis
▪ Content
Sample

40 Confidential
MediPharm Labs
Company Name:
Headquarter:
Revenue:
Website:
Company Profile
Sample
Sample

41 Confidential
MediPharm Labs
2020 2024 2028
Analysis
▪ Content
Sample

Research and Development Initiatives

43 Confidential
R&D Expenditure By Major Companies
Canada is well-positioned to lead the world in advancing R&D in
the cannabis sector. With the spread of legalization, R&D in the
cannabis sector can now be fully realized, placing Canada’s
cannabis industry in an excellent position to harness the power
of clinical data to further the evidence-based case
Canopy Growth has established an R&D arm, Canopy Health
Innovations, to its suite of subsidiaries with the intent of filing
new drug applications
Sample
Cannabis Sativa Inc. Canopy Growth Corporation
Emerald Health Therapeutics Inc CannMed Limited
GB Sciences Inc. Cara Therapeutics
Pfizer MediPharm Labs
Sample
Key Insights R&D Expenditure of Major Companies ($Bn), 2020

44 Confidential
R&D in Canada Cannabis Market
R&D may be helpful in many cases, such as:
▪ Advance the understanding of the chemicals already present in different strains of cannabis and the therapeutic properties of cannabis
for health conditions, as well as the potential effects of accumulated exposure over time
▪ Optimise production processes to improve yields and minimise costs
▪ Create new and innovative products that will better meet consumers’ needs and develop safer dosing methods for more precise ingestion
of cannabis
▪ Sufficient research may give more confidence to physicians on cannabis safety and efficacy and impact the number of prescriptions that
patients receive
▪ Cannabis innovation may drive new approaches in the extraction processes, allowing a higher and more precise yield of raw material
▪ Research into cannabis benefits for other health conditions yet to be explored
▪ To gain market share with innovative cannabis products
▪ To be recognized and accepted by regulatory agencies such as Health Canada, the Food and Drug Administration, and the European
Medicines Agency
Sample

Access and Reimbursement Scenario

46 Confidential
The Task Force recommends that the federal
government set a national minimum age of
purchase of 18, acknowledging the right of
provinces and territories to harmonize it with their
minimum age of purchase of alcohol
Access and Reimbursement Scenario
▪ Federal government use licensing and production controls to encourage a diverse, competitive market that also includes small
producers
▪ Implements a seed-to-sale tracking system to prevent diversion and enable product recalls
▪ Promotes environmental stewardship by implementing measures such as permitting outdoor production, with appropriate security
measures
▪ Content
▪ Content
General Reimbursement Environment
Key Market Access Considerations
1
Apply comprehensive restrictions to the
advertising and promotion of cannabis and related
merchandise by any means, including
sponsorship, endorsements and branding
2
Sample

48 Confidential
Key Industry Developments: Offerings and Approvals
In December 2020, Aphria Inc. and Tilray, Inc. (Canada) entered into a definitive agreement to combine their businesses and
create the world’s largest cannabis company. The Combined Company, supported by low-cost cultivation, processing, and
manufacturing facilities, would have a complete portfolio of branded Cannabis 2.0 products in Canada)
In November 2020, Canopy Growth Corporation launched a new line of CBD-infused beverages named Quatreau. These are
naturally flavored sparkling waters, which are available in both CBD-only and balanced (CBD + THC) offerings. The company
introduced this line of products as an alternative to sugary, caffeinated beverages or even alcohol
Content
Content

49 Confidential
Ongoing Clinical Trials
Dr. Burnham is a primary investigator in the first study in Canada to examine the impact of cannabis oil on the reduction of
convulsive seizures in adults. This phase III, double-blind, randomized, placebo-controlled trial, which looks at CBD
(cannabidiol), plus THC (tetrahydrocannabinol) – at a ratio of 16:1, will take about two years to complete
Avicanna Inc. is waiting for Health Canada to approve a clinical trial application at a top Toronto-based hospital, for a phase
II/III study of a cannabidiol cream to alleviate the painful blisters caused by epidermolysis bullosa [Butterfly Disease] in children
Content
Content

51 Confidential
Conclusion
Strong Demand
Increased Prevalence of
cannabis is expected to
increase exponentially due to
increase in awareness about
cannabis and its use
Challenges
There is a lack of acceptance of
cannabis as a medical therapeutic
because of there is an assumption
that cannabis is to be consumed
only via smoking
Availability of Funding
CCSA is investing $1.8 million
dollars in research on non-
therapeutic cannabis for
development of new products
Advancement in Treatment
Advancement in treatment of GI
Diseases have been trending
during this pandemic situation
due to its severity and relation
with COVID-19
Growing Start-ups
Canada has witnessed
development in startups in
diabetes market domain and is
leading to enormous growth

Canada Cannabis for GI Disease Market Report

Recommended

Recommended

More Related Content

What's hot

What's hot (16)

Similar to Canada Cannabis for GI Disease Market Report

Similar to Canada Cannabis for GI Disease Market Report (20)

More from Insights10

More from Insights10 (20)

Recently uploaded

Recently uploaded (20)

Canada Cannabis for GI Disease Market Report